Study Finds Ruxolitinib Effective, Safe for Children With AD
There were no significant safety signals in the younger pediatric population, and 'no treatment-emergent adverse events suggestive of systemic JAK inhibition,' Dr Lawrence Eichenfield said.
MDedge News
source https://www.medscape.com/s/viewarticle/997954?src=rss
MDedge News
source https://www.medscape.com/s/viewarticle/997954?src=rss
Comments
Post a Comment